Share

FIRSTonline Banner

Giuliani acquires Laboratoires Bailleul and accelerates growth in the trichology and dermatology segments.

The operation is part of Giuliani's international development path and further strengthens its market position in the core areas of trichology and dermatology.

Giuliani acquires Laboratoires Bailleul and accelerates growth in the trichology and dermatology segments.

we receive e we publish the following Press release spread by Image Building.

Giuliani, a leading pharmaceutical company in research in the area gastroenterology, trichology and dermatology owned by the Giuliani family, announces that it has completed the acquisition from the French Bigou family by Laboratoires Bailleul, an international company specializing in trichological and dermatological treatments.

Founded in France in 1939, Laboratories Bailleul si distinguishes in the trichological field in the treatment of alopecia based on minoxidil and offers a portfolio that also includes effective pharmaceutical products for pathologies dermatological (mycosis, rosacea) and gynecological (hormonal acne, contraception), distributed through a model that integrates medical information with direct sales in pharmacies.

“The operation strengthens our market position in two core segments of our business, the trichological and dermatological one, thanks to the solid strategic alignment between the two entities – explains Gaetano Colabucci, General Manager of Giuliani. – Our areas focusing therapies are perfectly superimposable, while the portfolios and geographies are complementary. Laboratoires Bailleul can also count on a pan-European platform with direct offices in the main markets and hubs outside Europe, for the benefit of the acceleration of the internationalization of Giuliani's brands and technologies.”

With a pilot plant turnover of around 75 million euros, Bailleul markets its products through a network of direct subsidiaries in France, Italy, Belgium, Portugal, Spain, Germany, Switzerland, Turkey, Greece and Slovakia, in addition to two non-European centers in Hong Kong and Mexico, and a network of qualified international distributors particularly active in China and the Middle East.

“This acquisition is perfectly consistent with the our strategic vision: to build a European champion in the treatment of dermatological and trichological pathologies, with solid foundations in Italy and a direct presence in key marketsWe share with Bailleul therapeutic focus, scientific culture and valuesWe will pool complementary portfolios, networks of relationships with specialists and industrial capabilities to to offer even more effective solutions to patients and healthcare professionals. This is a decisive step to accelerate the international growth of our brands and create sustainable value for all stakeholders,” he adds. Giammaria Giuliani.

In Italy, the juxtaposition of the Bailleul lines with the Giuliani brands will make the even more complete offer throughout the entire treatment process — from from drugs to supplements to dermocosmetics — strengthening the relationship with the medical profession and with pharmacies thanks to a further strengthened medical-scientific information structure.

At an international level, Bailleul's commercial and organizational network will allow Giuliani to rapidly acquire a significant pan-European presence, increasing critical mass and relevance in local markets and promoting a more efficient use of existing structures, with expected benefits also in terms of profitability.

This new operation – which will bring Giuliani aims to reach a turnover of approximately 250 million euros in 2026 – fits into the development path undertaken by the Company, which combines organic growth and acquisitions of strategic assets such as, for example, that of Nathura (acquired in 2021) and Biogena (acquired in 2023). 

Giuliani was assisted in the operation by Rothschild & Co e PwC as financial co-advisor. PwC also coordinated the due diligence and legal activities.

About Giuliani:

The history of the Giuliani pharmaceutical company begins in 1889, when Germano Giuliani, a pharmacist and chemist, arrived in Milan from Arco di Trento and purchased the old Lazzaretto pharmacy, one of the city's first. Since then, the family's research in gastroenterology, trichology, and dermatology has continued, initially focused on the famous Amaro Medicinale, before expanding into other fields, especially since 1937 when it became a fully-fledged pharmaceutical company.

Today the company employs 122 people at its headquarters, as well as 186 sales representatives and agents, while production is entirely outsourced.

Despite having become more managerial, it maintains its family character and continues to be owned by the Giuliani family, which is now in its fourth generation.

comments